CYP46A1 functional promoter haplotypes decipher genetic susceptibility to Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 21, Issue 4, 2010, Pages 1311-1323

  Li, Yan ^a   Chu, Leung Wing ^a,b   Wang, Binbin ^c   Yik, Ping Yiu ^a   Huriletemuer, ^d   Jin, Dong Yan ^a   Ma, Xu ^c   Song, You Qiang ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c NATIONAL RESEARCH INSTITUTE FOR FAMILY PLANNING   (China)

^d INNER MONGOLIA MEDICAL COLLEGE   (China)

Author keywords

Allelic expression; Alzheimer's disease; case control study; CYP46A1

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E EPSILON 4; CHOLESTEROL 24S HYDROXYLASE; LUCIFERASE; MYELIN TRANSCRIPTION FACTOR 1; OXYGENASE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN CELL; MONGOLIA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 78650458614     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-100765     Document Type: Article

References (39)

1. Puglielli L, Tanzi RE, Kovacs DM (2003) Alzheimer's disease: the cholesterol connection. Nat Neurosci 6, 345-351.
2. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A (2001) Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 322, 14471451.
3. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K (2005) Midlife cardiovascular risk factors and risk ofdementia in late life. Neurology 64, 277-281.
4. Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F (2001) Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10. [see comment]. Proc Natl Acad Sci USA 98, 5815-5820.
5. Wolozin B (2003) Cyp46 (24S-cholesterol hydroxylase): a genetic risk factor for Alzheimer disease. [comment]. Arch Neurol 60, 16-18.
6. Raffai RL, Weisgraber KH (2003) Cholesterol: from heart attacks to Alzheimer's disease. J Lipid Res 44, 1423-1430.
7. Li Y, Tacey K, Doil L, van Luchene R, Garcia V, Rowland C, Schrodi S, Leong D, Lau K, Catanese J, Sninsky J, Nowotny P, Holmans P, Hardy J, Powell J, Lovestone S, Thal L, Owen M, Williams J, Goate A, Grupe A (2004) Association of ABCA1 with late-onset Alzheimer's disease is not observed in a case-control study. Neurosci Lett 366, 268-271.
8. Lund EG, Guileyardo JM, Russell DW (1999) cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc Natl Acad Sci USA 96, 7238-7243.
9. Bjorkhem I, Lutjohann D, Breuer O, Sakinis A, Wennmalm A (1997) Importance of a novel oxidative mechanism for elimination ofbrain cholesterol. Turnover ofcholesterol and 24(S)-hydroxycholesterol in rat brain as measured with 18O2 techniques in vivo and in vitro. J Biol Chem 272, 30178-30184.
10. Bogdanovic N, Bretillon L, Lund EG, Diczfalusy U, Lannfelt L, Winblad B, Russell DW, Bjorkhem I (2001) On the turnover of brain cholesterol in patients with Alzheimer's disease. Abnormal induction of the cholesterol-catabolic enzyme CYP46 in glial cells. Neurosci Lett 314, 45-48.
11. Kuo YM, Emmerling MR, Bisgaier CL, Essenburg AD, Lam-pert HC, Drumm D, Roher AE (1998) Elevated low-density lipoprotein in Alzheimer's disease correlates with brain abeta 1-42 levels. Biochem Biophys Res Commun 252, 711-715.
12. Li Y, Chu LW, Chen YQ, Cheung BM, Leung RY, Yik PY, Ng KM, Mak W, Jin DY, St George-Hyslop P, Song YQ (2006) Intron 2 (T/C) CYP46 polymorphism is associated with Alzheimer's disease in Chinese patients. Dement Geriatr Cogn Disord 22, 399-404.
13. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report ofthe NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
14. Song YQ, Rogaeva E, Premkumar S, Brindle N, Kawarai T, Orlacchio A, Yu G, Levesque G, Nishimura M, Ikeda M, Pei Y, O'Toole C, Duara R, Barker W, Sorbi S, Freedman M, Farrer L, St George-Hyslop P (1998) Absence of association between Alzheimer disease and the -491 regulatory region polymorphism of APOE. Neurosci Lett 250, 189-192.
15. Li Y, Chu LW, Li Z, Yik PY, Song YQ (2009) A study on the association of the chromosome 12p13 locus with sporadic late-onset Alzheimer's disease in Chinese. Dement Geriatr Cogn Disord 27, 508-512.
16. Huriletemuer WB, Wang J, Wang G, Zhang C, Zhao S, Zhou S, Ma X, Wang de S. (2010) APOE epsilon4 is a high-risk factor for Alzheimer's disease in the Mongolian population. J Neurol Sci 15, 167-169.
17. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinfor-matics 21, 263-265.
18. Kehoe P, Wavrant-De F Vrieze, Crook R, Wu WS, Holmans P, Fenton I, Spurlock G, Norton N, Williams H, Williams N, Lovestone S, Perez-Tur J, Hutton M, Chartier-Harlin MC, Shears S, Roehl K, Booth J, Van Voorst W, Ramic D, Williams J, Goate A, Hardy J, Owen MJ (1999) A full genome scan for late onset Alzheimer's disease. Hum Mol Genet 8, 237-245.
19. Good PI (2005) Permutation, Parametric and Bootstrap Tests of Hypotheses, Springer.
20. Kim JG, Hudson LD (1992) Novel member of the zinc finger superfamily: A C2-HC finger that recognizes a glia-specific gene. Mol Cell Biol 12, 5632-5639.
21. Newton-Cheh C, Hirschhorn JN (2005) Genetic association studies of complex traits: design and analysis issues. Mut Res 573, 54-69.
22. Romm E, Nielsen JA, Kim JG, Hudson LD (2005) Myt1 family recruits histone deacetylase to regulate neural transcription. J Neurochem 93, 1444-1453.
23. Nielsen JA, Berndt JA, Hudson LD, Armstrong RC (2004) Myelin transcription factor 1 (Myt1) modulates the proliferation and differentiation of oligodendrocyte lineage cells. Mol CellNeurosci 25, 111-123.
24. Ma SL, Tang NL, Lam LC, Chiu HF (2006) Polymorphisms of the cholesterol 24-hydroxylase (CYP46A1) gene and the risk of Alzheimer's disease in a Chinese population. Int Psy-chogeriatr 18, 37-45.
25. Wang B, Zhang C, Zheng W, Lu Z, Zheng C, Yang Z, Wang L, Jin F (2004) Association between a T/C polymorphism in intron 2 ofcholesterol 24S-hydroxylase gene and Alzheimer's disease in Chinese. Neurosci Lett 369, 104-107.
26. Vana AC, Lucchinetti CF, Le TQ, Armstrong RC (2007) Myelin transcription factor 1 (Myt1) expression in demyeli-nated lesions of rodent and human CNS. GLIA 55, 687-697.
27. Wells NJ, Watanabe N, Tokusumi T, Jiang W, Verdecia MA, Hunter T (1999) The C-terminal domain of the Cdc2 inhibitory kinase Myt1 interacts with Cdc2 complexes and is required for inhibition of G(2)/M progression. J Cell Sci 112, 3361-3371.
28. Fattaey A, Booher RN (1997) Myt1: a Wee1-type kinase that phosphorylates Cdc2 on residue Thr14. Prog Cell Cycle Res 3, 233-240.
29. Shen M, Stukenberg PT, Kirschner MW, Lu KP (1998) The essential mitotic peptidyl-prolyl isomerase Pin1 binds and regulates mitosis-specific phosphoproteins. Genes Develop 12, 706-720.
30. Etzkorn FA (2006) Pin1 flips Alzheimer's switch. ACS Chem Biol 1,214-216.
31. Butterfield DA, Abdul HM, Opii W, Newman SF, Joshi G, Ansari MA, Sultana R (2006) Pin1 in Alzheimer's disease. J Neurochem 98, 1697-1706.
32. Tang BL, Liou YC (2007) Novel modulators of amyloid-beta precursor protein processing. J Neurochem 100, 314-323.
33. Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW (2004) Incipient Alzheimer's disease: mi-croarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci U S A 101, 2173-2178.
34. Brown J, 3rd, Theisler C, Silberman S, Magnuson D, Gottardi-Littell N, Lee JM, Yager D, Crowley J, Sambamurti K, Rahman MM, Reiss AB, Eckman CB, Wolozin B (2004) Differential expression of cholesterol hydroxylases in Alzheimer's disease. J Biol Chem 279, 34674-34681. (Pubitemid 39318097)
35. Teunissen CE, Floris S, Sonke M, Dijkstra CD, De Vries HE, Lutjohann D (2007) 24S-hydroxycholesterol in relation to disease manifestations of acute experimental autoimmune encephalomyelitis. J Neurosci Res 85, 1499-1505.
36. Ohyama Y, Meaney S, Heverin M, Ekstrom L, Brafman A, Shafir M, Andersson U, Olin M, Eggertsen G, Diczfalusy U, Feinstein E, Bjorkhem I (2006) Studies on the transcriptional regulation of cholesterol 24-hydroxylase (CYP46A1): marked insensitivity toward different regulatory axes. J Biol Chem 281, 3810-3820.
37. Milagre I NM, Gama MJ, Silva RF, Pascussi JM, Lechner MC, Rodrigues E. (2008) Transcriptional regulation ofthe human CYP46A1 brain-specific expression by Sp transcription factors. J Neurochem 106, 835-849.
38. Nunes MJ MI, Schnekenburger M, Gama MJ, Diederich M, Rodrigues E (2010) Sp proteins play a critical role in histone deacetylase inhibitor-mediated derepression of CYP46A1 gene transcription. J Neurochem 113, 418-431.
39. Labbaye C, Quaranta MT, Pagliuca A, Militi S, Licht JD, Testa U, Peschle C (2002) PLZF induces megakaryocytic development, activates Tpo receptor expression and interacts with GATA1 protein. Oncogene 21, 6669-6679.